Logo

Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrop… read more

Healthcare

Biotechnology

8 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$54.62

Price

-4.88%

-$2.80

Market Cap

$6.545b

Mid

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-25.0%

5y CAGR
Earnings

-$408.591m

-8.1%

1y CAGR

-36.7%

3y CAGR

-33.3%

5y CAGR
EPS

-$3.31

-0.6%

1y CAGR

-19.3%

3y CAGR

-12.0%

5y CAGR
Book Value

$253.784m

$523.543m

Assets

$269.759m

Liabilities

$203.833m

Debt
Debt to Assets

38.9%

-0.5x

Debt to EBITDA
Free Cash Flow

-$296.347m

+1.4%

1y CAGR

-28.8%

3y CAGR

-23.8%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases